Therefore, we first explored a system‐specific PD biomarker to establish a quantitative relationship between PK exposure and T2DM end points for SGLT2 inhibitors; then we validated this translational strategy using the fourth marketed same‐in‐class SGLT2 inhibitor (ertugliflozin). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.